127 related articles for article (PubMed ID: 35380874)
1. Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors.
Fosså SD; Dahl AA; Thorsen L; Hellesnes R; Kiserud CE; Tandstad T; Brydøy M; Haugnes HS; Myklebust TÅ
J Clin Oncol; 2022 Aug; 40(23):2588-2599. PubMed ID: 35380874
[TBL] [Abstract][Full Text] [Related]
2. Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.
Fosså SD; Haugnes HS; Dahl AA; Kiserud CE; Fosså A; Skalleberg J; Myklebust TÅ
Ann Oncol; 2023 Dec; 34(12):1165-1174. PubMed ID: 37739265
[TBL] [Abstract][Full Text] [Related]
3. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
[TBL] [Abstract][Full Text] [Related]
4. Risk of positive selection bias in longitudinal surveys among cancer survivors: Lessons learnt from the national Norwegian Testicular Cancer Survivor Study.
Fosså SD; Dahl AA; Myklebust TÅ; Kiserud CE; Nome R; Klepp OH; Brydøy M; Haugnes HS
Cancer Epidemiol; 2020 Aug; 67():101744. PubMed ID: 32652337
[TBL] [Abstract][Full Text] [Related]
5. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
6. Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study.
Hellesnes R; Myklebust TÅ; Bremnes RM; Karlsdottir Á; Kvammen Ø; Negaard HFS; Tandstad T; Wilsgaard T; Fosså SD; Haugnes HS
J Clin Oncol; 2021 Feb; 39(4):308-318. PubMed ID: 33356420
[TBL] [Abstract][Full Text] [Related]
7. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort.
Hellesnes R; Myklebust TÅ; Fosså SD; Bremnes RM; Karlsdottir Á; Kvammen Ø; Tandstad T; Wilsgaard T; Negaard HFS; Haugnes HS
J Clin Oncol; 2021 Nov; 39(32):3561-3573. PubMed ID: 34388002
[TBL] [Abstract][Full Text] [Related]
8. Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis.
Li H; Zhu C; Wu J; Ma Y; Jin X; Wei X; Wang K; Li H
Int Urol Nephrol; 2021 Mar; 53(3):471-477. PubMed ID: 33052518
[TBL] [Abstract][Full Text] [Related]
9. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Feldman DR; Ardeshir-Rouhani-Fard S; Monahan P; Sesso HD; Fung C; Williams AM; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Zaid MA; Lipshultz SE; Einhorn LH; Oeffinger KC; Travis LB; Fossa SD;
Clin Genitourin Cancer; 2018 Aug; 16(4):e761-e769. PubMed ID: 29534941
[TBL] [Abstract][Full Text] [Related]
10. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors.
Sprauten M; Haugnes HS; Brydøy M; Kiserud C; Tandstad T; Bjøro T; Bjerner J; Cvancarova M; Fosså SD; Oldenburg J
Ann Oncol; 2015 Oct; 26(10):2133-40. PubMed ID: 26265167
[TBL] [Abstract][Full Text] [Related]
11. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.
ArdeshirRouhaniFard S; Dinh PC; Monahan PO; Fossa SD; Huddart R; Fung C; Song Y; Feldman DR; Hamilton RJ; Vaughn DJ; Martin NE; Kollmannsberger C; Einhorn L; Kroenke K; Travis LB
Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1129-1138. PubMed ID: 33849970
[TBL] [Abstract][Full Text] [Related]
12. Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors.
Johannsdottir IMR; Hamre H; Fosså SD; Loge JH; Drolsum L; Lund MB; Nordsletten L; Kiserud C
J Adolesc Young Adult Oncol; 2017 Sep; 6(3):470-476. PubMed ID: 28837384
[TBL] [Abstract][Full Text] [Related]
13. A study of coping in long-term testicular cancer survivors.
Rutskij R; Gaarden T; Bremnes R; Dahl O; Finset A; Fossa SD; Klepp O; Sorebo O; Wist E; Dahl AA
Psychol Health Med; 2010 Mar; 15(2):146-58. PubMed ID: 20391232
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal kidney function outcome in aging testicular cancer survivors.
Nome RV; Cvancarova Småstuen M; Bjøro T; Kiserud CE; Fosså SD
Acta Oncol; 2020 Apr; 59(4):467-474. PubMed ID: 32043400
[No Abstract] [Full Text] [Related]
15. Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones.
Aschim EL; Oldenburg J; Kristiansen W; Giwercman A; Witczak O; Fosså SD; Haugen TB
Hum Reprod; 2014 Dec; 29(12):2844-51. PubMed ID: 25336703
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hypofunction in aging testicular cancer survivors.
Nome RV; Småstuen MC; Fosså SD; Kiserud CE; Åsvold BO; Bjøro T
Acta Oncol; 2021 Nov; 60(11):1452-1458. PubMed ID: 34351829
[TBL] [Abstract][Full Text] [Related]
17. Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer.
Blok JM; Groot HJ; Huele EH; de Wit R; Horenblas S; Nuver J; Groenewegen G; Bosch JLHR; Witjes JA; Tromp JM; de Brouwer PJM; van den Berg HA; Vanneste BGL; Smilde TJ; Aarts MJB; Gietema JA; Meijer RP; Schaapveld M
J Clin Oncol; 2021 Feb; 39(4):319-327. PubMed ID: 33119475
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
19. Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era.
Hellesnes R; Kvammen Ø; Myklebust TÅ; Bremnes RM; Karlsdottir Á; Negaard HFS; Tandstad T; Wilsgaard T; Fosså SD; Haugnes HS
Int J Cancer; 2020 Jul; 147(1):21-32. PubMed ID: 31597192
[TBL] [Abstract][Full Text] [Related]
20. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study.
Oldenburg J; Kraggerud SM; Brydøy M; Cvancarova M; Lothe RA; Fossa SD
J Transl Med; 2007 Dec; 5():70. PubMed ID: 18162130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
